Table 1. Open in new tab Patient...

Characteristics	Regimen started
Female, n (%)	67 (21.6)	167 (16.8)	115 (16.2)	0.088	349 (17.3)
Age (years), median (IQR)	39 (31–47)	36 (27–41)	37 (28–44)	0.002	37 (28–44)
Mode of HIV transmission, n (%)				0.002
IVDUs	21 (6.8)	44 (4.4)	38 (5.3)		103 (5.1)
homosexual contacts	138 (44.5)	552 (55.5)	405 (56.9)		1095 (54.3)
heterosexual contacts	133 (42.9)	322 (32.4)	231 (32.4)		686 (34.0)
other/unknown	18 (5.8)	76 (7.6)	38 (5.3)		132 (6.5)
Not Italian, n (%)	62 (20.0)	218 (21.9)	170 (23.9)	0.075	450 (22.3)
Calendar year of baseline, median (IQR)	2015 (2014–16)	2016 (2016–17)	2016 (2015–16)	<0.001	2016 (2015–17)
HBsAg positive, n (%)	4 (1.3)	4 (0.4)	9 (1.3)	<0.001	17 (0.8)
HCVAb positive, n (%)	27 (8.7)	49 (4.9)	41 (5.8)	<0.001	117 (5.8)
AIDS diagnosis, n (%)	26 (8.4)	48 (4.8)	26 (3.7)	0.006	100 (5.0)
CD4 count (cells/mm³), median (IQR)	330 (133–494)	343 (121–548)	380 (225–553)	<0.001	356 (151–540)
CD4 count ≤200 cells/mm³, n (%)^b	107 (35.4)	326 (33.3)	162 (22.9)	<0.001	595 (29.9)
CD8 count (cells/mm³), median (IQR)	852 (553–1214)	853 (542–1251)	900 (648–1325)	0.018	867 (588–1272)
VL (log₁₀ copies/mL), median (IQR)	4.93 (4.23–5.43)	4.73 (4.10–5.31)	4.71 (4.18–5.13)	0.089	4.75 (4.14–5.27)
Time from HIV diagnosis to starting cART (months), median (IQR)	2 (1–9)	1 (1–3)	2 (1–8)	<0.001	2 (1–5)
NRTIs started, n (%)				<0.001
abacavir + lamivudine	43 (13.9)	527 (53.0)	0 (0.0)		570 (28.3)
tenofovir disoproxil fumarate + emtricitabine	267 (86.1)	375 (37.7)	594 (83.4)		1236 (61.3)
tenofovir alafenamide + emtricitabine	0 (0.0)	92 (9.3)	118 (16.6)		210 (10.4)

Characteristics

Regimen started

raltegravir based, N = 310

dolutegravir based, N = 994

elvitegravir/ cobicistat based, N = 712

P^a

total, N = 2016

Female, n (%)

67 (21.6)

167 (16.8)

115 (16.2)

0.088

349 (17.3)

Age (years), median (IQR)

39 (31–47)

36 (27–41)

37 (28–44)

0.002

37 (28–44)

Mode of HIV transmission, n (%)

0.002

IVDUs

21 (6.8)

44 (4.4)

38 (5.3)

103 (5.1)

homosexual contacts

138 (44.5)

552 (55.5)

405 (56.9)

1095 (54.3)

heterosexual contacts

133 (42.9)

322 (32.4)

231 (32.4)

686 (34.0)

other/unknown

18 (5.8)

76 (7.6)

38 (5.3)

132 (6.5)

Not Italian, n (%)

62 (20.0)

218 (21.9)

170 (23.9)

0.075

450 (22.3)

Calendar year of baseline, median (IQR)

2015 (2014–16)

2016 (2016–17)

2016 (2015–16)

<0.001

2016 (2015–17)

HBsAg positive, n (%)

4 (1.3)

4 (0.4)

9 (1.3)

<0.001

17 (0.8)

HCVAb positive, n (%)

27 (8.7)

49 (4.9)

41 (5.8)

<0.001

117 (5.8)

AIDS diagnosis, n (%)

26 (8.4)

48 (4.8)

26 (3.7)

0.006

100 (5.0)

CD4 count (cells/mm³), median (IQR)

330 (133–494)

343 (121–548)

380 (225–553)

<0.001

356 (151–540)

CD4 count ≤200 cells/mm³, n (%)^b

107 (35.4)

326 (33.3)

162 (22.9)

<0.001

595 (29.9)

CD8 count (cells/mm³), median (IQR)

852 (553–1214)

853 (542–1251)

900 (648–1325)

0.018

867 (588–1272)

VL (log₁₀ copies/mL), median (IQR)

4.93 (4.23–5.43)

4.73 (4.10–5.31)

4.71 (4.18–5.13)

0.089

4.75 (4.14–5.27)

Time from HIV diagnosis to starting cART (months), median (IQR)

2 (1–9)

1 (1–3)

2 (1–8)

<0.001

2 (1–5)

NRTIs started, n (%)

<0.001

abacavir + lamivudine

43 (13.9)

527 (53.0)

0 (0.0)

570 (28.3)

tenofovir disoproxil fumarate + emtricitabine

267 (86.1)

375 (37.7)

594 (83.4)

1236 (61.3)

tenofovir alafenamide + emtricitabine

0 (0.0)

92 (9.3)

118 (16.6)

210 (10.4)

Characteristics	Regimen started
Female, n (%)	67 (21.6)	167 (16.8)	115 (16.2)	0.088	349 (17.3)
Age (years), median (IQR)	39 (31–47)	36 (27–41)	37 (28–44)	0.002	37 (28–44)
Mode of HIV transmission, n (%)				0.002
IVDUs	21 (6.8)	44 (4.4)	38 (5.3)		103 (5.1)
homosexual contacts	138 (44.5)	552 (55.5)	405 (56.9)		1095 (54.3)
heterosexual contacts	133 (42.9)	322 (32.4)	231 (32.4)		686 (34.0)
other/unknown	18 (5.8)	76 (7.6)	38 (5.3)		132 (6.5)
Not Italian, n (%)	62 (20.0)	218 (21.9)	170 (23.9)	0.075	450 (22.3)
Calendar year of baseline, median (IQR)	2015 (2014–16)	2016 (2016–17)	2016 (2015–16)	<0.001	2016 (2015–17)
HBsAg positive, n (%)	4 (1.3)	4 (0.4)	9 (1.3)	<0.001	17 (0.8)
HCVAb positive, n (%)	27 (8.7)	49 (4.9)	41 (5.8)	<0.001	117 (5.8)
AIDS diagnosis, n (%)	26 (8.4)	48 (4.8)	26 (3.7)	0.006	100 (5.0)
CD4 count (cells/mm³), median (IQR)	330 (133–494)	343 (121–548)	380 (225–553)	<0.001	356 (151–540)
CD4 count ≤200 cells/mm³, n (%)^b	107 (35.4)	326 (33.3)	162 (22.9)	<0.001	595 (29.9)
CD8 count (cells/mm³), median (IQR)	852 (553–1214)	853 (542–1251)	900 (648–1325)	0.018	867 (588–1272)
VL (log₁₀ copies/mL), median (IQR)	4.93 (4.23–5.43)	4.73 (4.10–5.31)	4.71 (4.18–5.13)	0.089	4.75 (4.14–5.27)
Time from HIV diagnosis to starting cART (months), median (IQR)	2 (1–9)	1 (1–3)	2 (1–8)	<0.001	2 (1–5)
NRTIs started, n (%)				<0.001
abacavir + lamivudine	43 (13.9)	527 (53.0)	0 (0.0)		570 (28.3)
tenofovir disoproxil fumarate + emtricitabine	267 (86.1)	375 (37.7)	594 (83.4)		1236 (61.3)
tenofovir alafenamide + emtricitabine	0 (0.0)	92 (9.3)	118 (16.6)		210 (10.4)

Table 1.

Open in new tab

Patient characteristics according to the different INSTI-containing regimens

Characteristics	Regimen started
Characteristics	raltegravir based, N = 310	dolutegravir based, N = 994	elvitegravir/ cobicistat based, N = 712	P^a	total, N = 2016
Female, n (%)	67 (21.6)	167 (16.8)	115 (16.2)	0.088	349 (17.3)
Age (years), median (IQR)	39 (31–47)	36 (27–41)	37 (28–44)	0.002	37 (28–44)
Mode of HIV transmission, n (%)				0.002
IVDUs	21 (6.8)	44 (4.4)	38 (5.3)		103 (5.1)
homosexual contacts	138 (44.5)	552 (55.5)	405 (56.9)		1095 (54.3)
heterosexual contacts	133 (42.9)	322 (32.4)	231 (32.4)		686 (34.0)
other/unknown	18 (5.8)	76 (7.6)	38 (5.3)		132 (6.5)
Not Italian, n (%)	62 (20.0)	218 (21.9)	170 (23.9)	0.075	450 (22.3)
Calendar year of baseline, median (IQR)	2015 (2014–16)	2016 (2016–17)	2016 (2015–16)	<0.001	2016 (2015–17)
HBsAg positive, n (%)	4 (1.3)	4 (0.4)	9 (1.3)	<0.001	17 (0.8)
HCVAb positive, n (%)	27 (8.7)	49 (4.9)	41 (5.8)	<0.001	117 (5.8)
AIDS diagnosis, n (%)	26 (8.4)	48 (4.8)	26 (3.7)	0.006	100 (5.0)
CD4 count (cells/mm³), median (IQR)	330 (133–494)	343 (121–548)	380 (225–553)	<0.001	356 (151–540)
CD4 count ≤200 cells/mm³, n (%)^b	107 (35.4)	326 (33.3)	162 (22.9)	<0.001	595 (29.9)
CD8 count (cells/mm³), median (IQR)	852 (553–1214)	853 (542–1251)	900 (648–1325)	0.018	867 (588–1272)
VL (log₁₀ copies/mL), median (IQR)	4.93 (4.23–5.43)	4.73 (4.10–5.31)	4.71 (4.18–5.13)	0.089	4.75 (4.14–5.27)
Time from HIV diagnosis to starting cART (months), median (IQR)	2 (1–9)	1 (1–3)	2 (1–8)	<0.001	2 (1–5)
NRTIs started, n (%)				<0.001
abacavir + lamivudine	43 (13.9)	527 (53.0)	0 (0.0)		570 (28.3)
tenofovir disoproxil fumarate + emtricitabine	267 (86.1)	375 (37.7)	594 (83.4)		1236 (61.3)
tenofovir alafenamide + emtricitabine	0 (0.0)	92 (9.3)	118 (16.6)		210 (10.4)

Characteristics	Regimen started
Characteristics	raltegravir based, N = 310	dolutegravir based, N = 994	elvitegravir/ cobicistat based, N = 712	P^a	total, N = 2016
Female, n (%)	67 (21.6)	167 (16.8)	115 (16.2)	0.088	349 (17.3)
Age (years), median (IQR)	39 (31–47)	36 (27–41)	37 (28–44)	0.002	37 (28–44)
Mode of HIV transmission, n (%)				0.002
IVDUs	21 (6.8)	44 (4.4)	38 (5.3)		103 (5.1)
homosexual contacts	138 (44.5)	552 (55.5)	405 (56.9)		1095 (54.3)
heterosexual contacts	133 (42.9)	322 (32.4)	231 (32.4)		686 (34.0)
other/unknown	18 (5.8)	76 (7.6)	38 (5.3)		132 (6.5)
Not Italian, n (%)	62 (20.0)	218 (21.9)	170 (23.9)	0.075	450 (22.3)
Calendar year of baseline, median (IQR)	2015 (2014–16)	2016 (2016–17)	2016 (2015–16)	<0.001	2016 (2015–17)
HBsAg positive, n (%)	4 (1.3)	4 (0.4)	9 (1.3)	<0.001	17 (0.8)
HCVAb positive, n (%)	27 (8.7)	49 (4.9)	41 (5.8)	<0.001	117 (5.8)
AIDS diagnosis, n (%)	26 (8.4)	48 (4.8)	26 (3.7)	0.006	100 (5.0)
CD4 count (cells/mm³), median (IQR)	330 (133–494)	343 (121–548)	380 (225–553)	<0.001	356 (151–540)
CD4 count ≤200 cells/mm³, n (%)^b	107 (35.4)	326 (33.3)	162 (22.9)	<0.001	595 (29.9)
CD8 count (cells/mm³), median (IQR)	852 (553–1214)	853 (542–1251)	900 (648–1325)	0.018	867 (588–1272)
VL (log₁₀ copies/mL), median (IQR)	4.93 (4.23–5.43)	4.73 (4.10–5.31)	4.71 (4.18–5.13)	0.089	4.75 (4.14–5.27)
Time from HIV diagnosis to starting cART (months), median (IQR)	2 (1–9)	1 (1–3)	2 (1–8)	<0.001	2 (1–5)
NRTIs started, n (%)				<0.001
abacavir + lamivudine	43 (13.9)	527 (53.0)	0 (0.0)		570 (28.3)
tenofovir disoproxil fumarate + emtricitabine	267 (86.1)	375 (37.7)	594 (83.4)		1236 (61.3)
tenofovir alafenamide + emtricitabine	0 (0.0)	92 (9.3)	118 (16.6)		210 (10.4)

HBsAg, hepatitis B surface antigen; HCVAb, anti-hepatitis C virus antibody test.

χ² or Kruskal–Wallis test as appropriate.

29 Cases with missing CD4 cell count.

This Feature Is Available To Subscribers Only